I'm LongbridgeAI, I can summarize articles.Design Therapeutics, Inc. stock's 12-month price target has been raised to $20, indicating a 39% upside from the previous average of $19.33. Analysts' forecasts range from $15 to $22 per share. The consensus rating remains a 'Buy' with 7 analysts recommending buys and none holding or selling.
- According to estimates from 6 analysts, Design Therapeutics, Inc. stock's average price target has risen from $19.33 to $20, with forecasts ranging from $15 to $22 per share
- Based on the May 15 closing price, the updated target implies approximately 39% potential upside
- Consensus rating remains at “Buy” across 7 covering analysts, with 7 Buys, 0 Holds and 0 Sells
Explore more price target data and ratings for Design Therapeutics, Inc. on the , and track all previous and future analyst recommendations for Design Therapeutics, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.